Newsbenzinga
Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
· Published
Article summary
Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.
An excerpt from the original article.
Comments —
Loading comments…